![Philipp Mathieu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Philipp Mathieu was President & Chief Executive Officer at Immunovia AB from 2022 to 2023.
Mr. Mathieu completed graduate studies at Bayes Business School.
| Unternehmen | Position | Ende |
|---|---|---|
| IMMUNOVIA AB | Vorstandsvorsitzender | 30.04.2023 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 2 |
|---|---|
Bayes Business School
 Bayes Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immunovia AB
 Immunovia AB Pharmaceuticals: MajorHealth Technology Provides blood-based test for diagnosis of pancreatic cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
